Leniobio Closes Its Series-A Extension Round And Strengthens Its Board Of Directors
PRIVATEMar 07, 2022
Round Type
Series A
Düsseldorf
Description
LenioBio GmbH, a German life sciences biotech offering a disruptive protein manufacturing technology, ALiCE®, closed its Series-A Extension round with a total investment volume of €11.5 million. The investment round, which was closed in November 2021, is led by LenioBio's current investor Bridford Group, a PE investor focusing on founder-led businesses with long-term growth potential and concerned with societal or environmental welfare.
Who to call at Lenio Bio, and when
A new round usually means Lenio Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Lenio Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Lenio Bio, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Lenio Bio
Location
Düsseldorf, North Rhine-Westphalia, Germany
About
LenioBio is a protein expression platform company committed to the advancement of transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.
LenioBio was established as a legal entity in Germany in September 2016, with offices in Dusseldorf and R&D and production labs in Aachen. For more information visit www.leniobio.com and follow LenioBio on LinkedIn.
Logo - https://mma.prnewswire.com/media/1758134/LenioBio_Logo.jpg
SOURCE LenioBio GmbH
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lenio Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Düsseldorf